Astellas Regains Japan Losses With Xtandi Expansion
This article was originally published in PharmAsia News
Executive Summary
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.
You may also be interested in...
PREVAIL Impresses, But Prostate Docs Wary Of Declaring Victory For Xtandi Over Zytiga
Bullish analysts predicted Xtandi easily wins over first-to-market Zytiga in pre-chemo prostate cancer, based on PREVAIL findings. But in the formal presentation at the ASCO GU meeting, clinicians were more reluctant to compare the two drugs and took a more nuanced interpretation of the data, given the important differences in study designs.
J.P. Morgan Notebook: Tuesday January 14
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the second day of the 2014 J.P. Morgan health care conference, including news from ZS Pharma, Aisling Capital, Astellas, and Moderna.
Broader Indications For Tarceva As Astellas Scales Back In The U.S.
The Japanese pharma is consolidating its U.S. operations, including the shuttering of OSI, where Tarceva initially was developed, as the cancer drug gains another indication with a companion diagnostic.